Compare Rivian Automotive, Inc. (RIVN) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rivian Automotive, Inc. vs Sanofi SA — how do they compare? Rivian Automotive, Inc. trades at $17.13 (market cap $25.71B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Sanofi SA is far larger — about 4.1× Rivian Automotive, Inc.'s market cap, and Sanofi SA pays a 5.53% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| RIVN | SNY | |
|---|---|---|
Market Cap | $25.71B | $104.85B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $52.34 |
52-Week Low | $11.64 | $41.33 |
Enterprise Value | $27.45B | $121.38B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $17.76, up 1.75% on the day, with a neutral technical outlook and bullish moving averages. The company continues to post significant losses, with a net income margin of -63.62% in 2025, though revenue grew to $5.39 billion. Recent news highlights focus on the upcoming R2 vehicle launch and a challenging EV market environment.
Rivian's investment case hinges on successful execution of the R2 launch and path to profitability, but faces substantial risks from cash burn, competition, and macroeconomic pressures. Analyst consensus is a Buy with a $19.22 price target, suggesting moderate upside potential from current levels if operational improvements materialize.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rivian Automotive, Inc.
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
